Nephrology Dialysis Transplantation Reports Phase 2 Data of Investigational ... - Nasdaq
Nephrology Dialysis Transplantation Reports Phase 2 Data of Investigational ... Nasdaq SAN FRANCISCO, Aug. 12, 2015 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq:FGEN), a research-based biopharmaceutical company, today announced that Nephrology Dialysis Transplantation has published encouraging Phase 2a safety and efficacy ...